Skip to content

Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation

Circulating MicroRNA Isoforms as Biomarkers in Hepatocellular Carcinoma and Associated Liver Transplantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02412579
Enrollment
40
Registered
2015-04-09
Start date
2015-03-31
Completion date
2022-03-17
Last updated
2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

HCC, Liver Cancer

Brief summary

The purpose of this study is to determine whether genetic markers unique to liver cancer are present and to assess usefulness as a diagnostic tool.

Detailed description

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and a growing trend worldwide. Decision-making regarding treatment for patients is limited by the lack of clinically actionable biomarkers. This is pronounced in the case for determining and monitoring liver transplant recipients. In an effort to improve diagnosis, the use of circulating serum-based microRNA isoforms (isomiRs) can serve as non-invasive, screening biomarkers in HCC patients pre- and post-transplantation of the liver.

Interventions

Sponsors

Baylor Research Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with the diagnosis of HCC who are on the wait list for liver transplantation * Patients with the diagnosis of HCC who have been admitted to hospital, scheduled to undergo liver transplantation within the following 24 hours. * Age Range: 18 to 75 years old

Exclusion criteria

* Patients with metastatic HCC and patients with the diagnosis of HCC who are not on the wait list for liver transplantation. * Patients older than 75 years old and younger than 18 years old. * Patients who are unable to consent. * Pregnant patients.

Design outcomes

Primary

MeasureTime frame
Using next-generation sequencing methods to detect isomiRs across different HCC cohorts at all stages undergoing liver transplantation.One year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026